Susan Rohr, DO
Pulmonary Disease · Sioux Falls, SDNPI 1558317826
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $251 of the $281 with a category attached, or 89.3%. 8 manufacturers reported payments, led by Sanofi at 33.8% of the total. 2025 is the largest year on record at $101, 4.0 times the $25 reported in 2019. That places this record below the midpoint for pulmonary disease clinicians in SD, where the typical reported total is $424.
Across 11 payments — averaging $25.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$95
- Baxter Healthcare$46
- Inspire Medical Systems, Inc.$45
- Boehringer Ingelheim$25
- Merck$25
- Insmed, Inc.$17
- plus $28 from 2 others
What the payments were for
- Food & beverage$25189%
- Education$3011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 1 | $95 |
| Baxter Healthcare | 2 | $46 |
| Inspire Medical Systems, Inc. | 2 | $45 |
| Boehringer Ingelheim | 1 | $25 |
| Merck | 2 | $25 |
| Insmed, Inc. | 1 | $17 |
| Harmony Biosciences LLC | 1 | $14 |
| AstraZeneca | 1 | $14 |
How this compares
$281 in reported general payments places this provider in the 35th percentile of 35 pulmonary disease providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $17,469 |
| Incruse ElliptaUmeclidinium Bromide | 42 | $13,338 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $10,771 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $5,803 |
| Spiriva HandihalerTiotropium Bromide | 12 | $5,779 |
| Ivermectin | 15 | $3,313 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $3,022 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $978 |
| Montelukast Sodium | 44 | $222 |
| Prednisone | 29 | $206 |
| Cyclobenzaprine Hcl | 12 | $120 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Sioux Falls
- Joevasanth DevasahayamSioux Falls$8K
- Matthew TaylorSioux Falls$8K
- Fady JamousSioux Falls$6K
- Rizan HajalSioux Falls$5K
- Kaitlin BranickSioux Falls$5K
- Anna PlemmonsSioux Falls$3K
- Mohammed AwadSioux Falls$2K
- Ashraf ElshamiSioux Falls$2K
- John YuSioux Falls$2K
- Rajaganesh RajagopalanSioux Falls$964
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.